Subcutaneous route and pharmacology of metoclopramide - SOPHA-Méto - SOPHA-Meto

CHU de Bordeaux0 个研究点目标入组 24 人开始时间: 2015年6月25日最近更新: 2019年4月30日

适应症

试验速览

暂无简介。

•- Man or woman aged at least 18 years
•- Patient hospitalized at the University Hospital of Bordeaux on palliative department
•- Patients with life expectancy estimated by the investigator, is greater than 3 weeks
•- Patients suffering from nausea the day of inclusion with a score greater than or equal to 3/10 on a numerical scale and / or had at least one vomiting within three days prior to inclusion
•- Patient can be infused IV and SC
•- Patient can communicate verbally or in writing
•- Patient has given its written consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 18
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 6

•- Pregnant or breastfeeding women
•- Current treatment for severe and progressive threatening disease
•- Treatment with oral or injectable metoclopramide within 3 days prior to inclusion
•- Current Treatment with levodopa or dopamine agonists
•- Neuroleptic Processing
•- Presence of clinical signs of encephalopathy (flapping, drowsiness, disorientation)
•- Patient achieved a lesion occlusive syndrome according to the investigator,
•- Patients at risk of gastrointestinal perforation according to the investigator
•- Patient with clinical signs of gastrointestinal bleeding
•- Patient with dyskinesia
•- Patient with an extra-pyramidal syndrome
•- Known or suspected patients with pheochromocytoma
•- History of allergy to metoclopramide
•- History of methemoglobinemia with metoclopramide
•- History deficit NADH-cytochrome b5 reductase-
•- Patient deprived of liberty by judicial or administrative decision
•- Major protected by law
•- Patient exclusion period relative over another protocol.

发起方

CHU de Bordeaux